199 related articles for article (PubMed ID: 38167551)
21. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
[TBL] [Abstract][Full Text] [Related]
22. Vasari Scoring System in Discerning between Different Degrees of Glioma and IDH Status Prediction: A Possible Machine Learning Application?
Gemini L; Tortora M; Giordano P; Prudente ME; Villa A; Vargas O; Giugliano MF; Somma F; Marchello G; Chiaramonte C; Gaetano M; Frio F; Di Giorgio E; D'Avino A; Tortora F; D'Agostino V; Negro A
J Imaging; 2023 Mar; 9(4):. PubMed ID: 37103226
[TBL] [Abstract][Full Text] [Related]
23. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
[TBL] [Abstract][Full Text] [Related]
24. Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Regnery S; Behl NGR; Platt T; Weinfurtner N; Windisch P; Deike-Hofmann K; Sahm F; Bendszus M; Debus J; Ladd ME; Schlemmer HP; Rieken S; Adeberg S; Paech D
Neuroimage Clin; 2020; 28():102427. PubMed ID: 33002860
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Ki-67 expression levels in IDH-wildtype glioblastoma using logistic regression modelling of VASARI features.
Bai L; Jiang J; Zhou J
Neurosurg Rev; 2023 Dec; 47(1):20. PubMed ID: 38135816
[TBL] [Abstract][Full Text] [Related]
26. The combination of radiomics features and VASARI standard to predict glioma grade.
You W; Mao Y; Jiao X; Wang D; Liu J; Lei P; Liao W
Front Oncol; 2023; 13():1083216. PubMed ID: 37035137
[TBL] [Abstract][Full Text] [Related]
27. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status.
Hyare H; Rice L; Thust S; Nachev P; Jha A; Milic M; Brandner S; Rees J
Eur J Radiol; 2019 May; 114():120-127. PubMed ID: 31005161
[TBL] [Abstract][Full Text] [Related]
28. Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
Peng H; Huo J; Li B; Cui Y; Zhang H; Zhang L; Ma L
J Magn Reson Imaging; 2021 May; 53(5):1399-1407. PubMed ID: 33179832
[TBL] [Abstract][Full Text] [Related]
29. Prediction of H3K27M mutation status of diffuse midline gliomas using MRI features.
Chauhan RS; Kulanthaivelu K; Kathrani N; Kotwal A; Bhat MD; Saini J; Prasad C; Chakrabarti D; Santosh V; Uppar AM; Srinivas D
J Neuroimaging; 2021 Nov; 31(6):1201-1210. PubMed ID: 34189806
[TBL] [Abstract][Full Text] [Related]
30. Multiparametric MR radiomics in brain glioma: models comparation to predict biomarker status.
He J; Ren J; Niu G; Liu A; Wu Q; Xie S; Ma X; Li B; Wang P; Shen J; Wu J; Gao Y
BMC Med Imaging; 2022 Aug; 22(1):137. PubMed ID: 35931979
[TBL] [Abstract][Full Text] [Related]
31. The added prognostic value of radiological phenotype combined with clinical features and molecular subtype in anaplastic gliomas.
Lee M; Han K; Ahn SS; Bae S; Choi YS; Hong JB; Chang JH; Kim SH; Lee SK
J Neurooncol; 2019 Mar; 142(1):129-138. PubMed ID: 30604396
[TBL] [Abstract][Full Text] [Related]
32. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
33. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
[TBL] [Abstract][Full Text] [Related]
34. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
[TBL] [Abstract][Full Text] [Related]
35. Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O
Zhang S; Sun H; Su X; Yang X; Wang W; Wan X; Tan Q; Chen N; Yue Q; Gong Q
J Magn Reson Imaging; 2021 Jul; 54(1):197-205. PubMed ID: 33393131
[TBL] [Abstract][Full Text] [Related]
36. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
37. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
38. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
39. Prediction of Molecular Mutations in Diffuse Low-Grade Gliomas using MR Imaging Features.
Shboul ZA; Chen J; M Iftekharuddin K
Sci Rep; 2020 Feb; 10(1):3711. PubMed ID: 32111869
[TBL] [Abstract][Full Text] [Related]
40. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
